MX2010007038A - Microorganismos para mejorar el estado de salud de individuos con desordenes relacionados con la ingesta de gluten. - Google Patents

Microorganismos para mejorar el estado de salud de individuos con desordenes relacionados con la ingesta de gluten.

Info

Publication number
MX2010007038A
MX2010007038A MX2010007038A MX2010007038A MX2010007038A MX 2010007038 A MX2010007038 A MX 2010007038A MX 2010007038 A MX2010007038 A MX 2010007038A MX 2010007038 A MX2010007038 A MX 2010007038A MX 2010007038 A MX2010007038 A MX 2010007038A
Authority
MX
Mexico
Prior art keywords
microorganisms
individuals
health
improving
disorders related
Prior art date
Application number
MX2010007038A
Other languages
English (en)
Inventor
Yolanda Sanz Herranz
Esther Sanchez Sanchez
Marcela Susana Medina
Giada De Palma
Inmaculada Nadal Gimenez
Original Assignee
Consejo Superior Investigacion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior Investigacion filed Critical Consejo Superior Investigacion
Publication of MX2010007038A publication Critical patent/MX2010007038A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales

Abstract

La presente invención aporta microorganismos para el tratamiento de alergias alimentarias, más concretamente la enfermedad celiaca, así como métodos para su sección. Sus mecanismos de acción incluyen: (i) la regulación de la respuesta inmunológica innata y adaptativa; (ii) la reducción de la concentración de epítopos tóxicos en la luz intestinal; (iii) el fortalecimiento de la función barrera defensiva frente a bacterias y antígenos perjudiciales, y (iv) el aporte de actividades enzimáticas que favorecen la digestión.
MX2010007038A 2007-12-24 2008-12-23 Microorganismos para mejorar el estado de salud de individuos con desordenes relacionados con la ingesta de gluten. MX2010007038A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200703427A ES2343499B1 (es) 2007-12-24 2007-12-24 Microorganismos para mejorar el estado de salud de individuos con desordenes relacionados con la ingesta de gluten.
PCT/ES2008/070243 WO2009080862A1 (es) 2007-12-24 2008-12-23 Microorganismos para mejorar el estado de salud de individuos con desordenes relacionados con la ingesta de gluten

Publications (1)

Publication Number Publication Date
MX2010007038A true MX2010007038A (es) 2010-10-15

Family

ID=40800750

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010007038A MX2010007038A (es) 2007-12-24 2008-12-23 Microorganismos para mejorar el estado de salud de individuos con desordenes relacionados con la ingesta de gluten.

Country Status (16)

Country Link
US (1) US8501169B2 (es)
EP (1) EP2236598B1 (es)
JP (1) JP5693232B2 (es)
KR (1) KR20100110341A (es)
CN (1) CN101983237B (es)
AU (1) AU2008341708B2 (es)
BR (1) BRPI0819533B1 (es)
CA (1) CA2710666C (es)
CY (1) CY1113848T1 (es)
DK (1) DK2236598T3 (es)
ES (2) ES2343499B1 (es)
MX (1) MX2010007038A (es)
PL (1) PL2236598T3 (es)
PT (1) PT2236598E (es)
SI (1) SI2236598T1 (es)
WO (1) WO2009080862A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110081320A1 (en) * 2009-10-06 2011-04-07 Nubiome, Inc. Treatment/Cure of Autoimmune Disease
US20140187474A1 (en) * 2011-02-16 2014-07-03 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic use of mucin glycans
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
CN104780932A (zh) 2012-02-29 2015-07-15 伊西康内外科公司 微生物区系的组合物及与其相关的方法
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
FI127483B (en) 2014-06-11 2018-07-13 Gut Guide Oy Microbial marker for celiac disease and related product
JP6868562B2 (ja) 2014-10-31 2021-05-19 ペンデュラム セラピューティクス， インコーポレイテッド 障害の微生物的処置および診断に関する方法および組成物
EP3222281B1 (en) * 2014-11-19 2020-01-08 Kabushiki Kaisha Yakult Honsha Preventive and therapeutic agent for celiac disease
MX2017008449A (es) 2014-12-23 2017-10-12 4D Pharma Res Ltd Polipeptido de pirina y modulacion inmune.
PT3065748T (pt) 2014-12-23 2018-02-28 4D Pharma Res Ltd Uma estirpe de bacteroides thetaiotaomicron e o seu uso na redução da inflamação
ES2575828B1 (es) 2014-12-31 2017-07-07 Universidad De León Empleo de probióticos en el incremento de la fertilidad masculina
LT3360559T (lt) 2015-06-15 2019-12-27 4D Pharma Research Limited Kompozicijos, apimančios bakterijų kamienus
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
TWI733676B (zh) 2015-06-15 2021-07-21 英商4D製藥研究有限公司 包含細菌菌株之組合物
SI3240554T1 (sl) 2015-06-15 2019-12-31 4D Pharma Research Limited, Blautia stercosis in wexlerae za uporabo v zdravljenju vnetnih in avtoimunskih bolezni
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
GB201515557D0 (en) * 2015-09-02 2015-10-14 14M Genomics Ltd Method of sequencing
BR112018010089A2 (pt) 2015-11-20 2018-11-13 4D Pharma Res Ltd composições compreendendo cepas bacterianas
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
SG11201807195VA (en) 2016-03-04 2018-09-27 4D Pharma Plc Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
EP3222282A1 (en) * 2016-03-21 2017-09-27 Bionou Research, S.L. Use of probiotics in the treatment and/or prevention of psoriasis
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
EP3272396A1 (en) * 2016-07-18 2018-01-24 Bionou Research, S.L. Use of probiotics in the treatment and/or prevention of atopic dermatitis
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
US20200061131A1 (en) * 2016-12-16 2020-02-27 Vedanta Biosciences, Inc. Methods and compositions for determining bacterial integrity
PT3630136T (pt) 2017-05-22 2021-06-11 4D Pharma Res Ltd Composições que compreendem estirpes bacterianas
MA41708A (fr) 2017-05-24 2020-04-08 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
RS60910B1 (sr) 2017-06-14 2020-11-30 4D Pharma Res Ltd Kompozicije koje sadrže bakterijski soj roda megasphaera i njihove upotrebe
LT3638271T (lt) 2017-06-14 2021-01-11 4D Pharma Research Limited Kompozicijos, apimančios bakterines padermes
JP2020532515A (ja) 2017-08-30 2020-11-12 ペンデュラム セラピューティクス， インコーポレイテッド マイクロバイオーム関連障害の処置のための方法および組成物
JP7273824B2 (ja) * 2017-12-29 2023-05-15 ソシエテ・デ・プロデュイ・ネスレ・エス・アー セルピン産生
WO2020069282A1 (en) * 2018-09-27 2020-04-02 Research Development Foundation Methods and probiotic compositions for the treatment of bone disorders
EP3920908A4 (en) * 2019-02-08 2022-10-05 McMaster University USE OF ARYL HYDROCARBON RECEPTOR ACTIVATORS FOR THE TREATMENT OF GLUTEN-INDUCED GASTROINTESTINAL DISEASES
MX2022007796A (es) 2019-12-23 2023-01-24 Evonik Operations Gmbh Preparacion que comprende cepas probioticas para la degradacion del gluten.
CN112694992B (zh) * 2020-12-30 2023-02-21 江南大学 一株可缓解腹泻的两歧双歧杆菌及其应用
CN115400154A (zh) * 2022-08-10 2022-11-29 深圳未知君生物科技有限公司 长双歧杆菌在制备治疗自闭症谱系障碍的药物中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7285526B2 (en) 1995-07-14 2007-10-23 Meiogen Biotechnology Corporation Interferon antagonists useful for the treatment of interferon related diseases
ID29150A (id) * 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
US6562943B1 (en) 1999-04-21 2003-05-13 Zycos, Inc. Peptide epitopes recognized by disease promoting CD4+ T lymphocytes
PE20030284A1 (es) * 2001-07-26 2003-05-01 Alimentary Health Ltd Cepas de bifidobacterium
US7320788B2 (en) 2002-02-14 2008-01-22 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for Celiac Sprue
ITMI20020399A1 (it) * 2002-02-28 2003-08-28 Ct Sperimentale Del Latte S P Composizioni dietetiche e/o farmaceutiche per uso umano e/o animale abase di preparati microbici probiotici
US7202216B2 (en) 2002-05-14 2007-04-10 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
WO2004076615A2 (en) * 2003-02-27 2004-09-10 Bioneer A/S Immunomodulating probiotic compounds
GB0323039D0 (en) * 2003-10-01 2003-11-05 Danisco Method
US7579313B2 (en) 2003-11-18 2009-08-25 The Board Of Trustees Of The Leland Stanford Junior University Transglutaminase inhibitors and methods of use thereof
US7563864B2 (en) 2004-04-26 2009-07-21 Celiac Sprue Research Foundation Prolyl endopeptidase mediated destruction of T cell epitopes in whole gluten
WO2006097949A1 (en) * 2005-03-16 2006-09-21 Actial Farmacêutica, Lda. Mixture of at least 6 species of lactic acid bacteria and/or bifidobacteria in the manufacture of sourdough
US8071101B2 (en) 2005-11-03 2011-12-06 Avaxia Biologics, Inc. Antibody therapy for treatment of diseases associated with gluten intolerance
ES2459018T3 (es) 2006-02-09 2014-05-07 Alba Therapeutics Corporation Formulaciones de efectores de la unión estrecha
WO2007108763A1 (en) 2006-03-17 2007-09-27 Probac Ab Use of lactobacillus strains for promoting immunotolerance in autoimmune disease

Also Published As

Publication number Publication date
US8501169B2 (en) 2013-08-06
JP2011507540A (ja) 2011-03-10
US20100310520A1 (en) 2010-12-09
PT2236598E (pt) 2013-04-02
ES2343499A1 (es) 2010-08-02
BRPI0819533A2 (pt) 2014-10-14
KR20100110341A (ko) 2010-10-12
EP2236598B1 (en) 2012-12-26
AU2008341708B2 (en) 2014-07-17
CA2710666A1 (en) 2009-07-02
CA2710666C (en) 2018-12-04
EP2236598A4 (en) 2012-01-25
ES2402183T3 (es) 2013-04-29
WO2009080862A1 (es) 2009-07-02
PL2236598T3 (pl) 2013-08-30
BRPI0819533B1 (pt) 2018-06-05
CN101983237B (zh) 2013-06-12
JP5693232B2 (ja) 2015-04-01
EP2236598A1 (en) 2010-10-06
ES2343499B1 (es) 2011-06-10
CY1113848T1 (el) 2016-07-27
DK2236598T3 (da) 2013-04-02
CN101983237A (zh) 2011-03-02
SI2236598T1 (sl) 2013-08-30
AU2008341708A1 (en) 2009-07-02

Similar Documents

Publication Publication Date Title
MX2010007038A (es) Microorganismos para mejorar el estado de salud de individuos con desordenes relacionados con la ingesta de gluten.
MX350325B (es) Bacteria para usarse como un probiotico para aplicaciones nutricionales y medicas.
MX2011011670A (es) Inmunoglobulinas de dominio variable dual y usos de las mismas.
MY160894A (en) Oligosaccharide composition for treating skin diseases
WO2009013543A3 (en) Targeted binging agents directed to kdr and uses thereof - 035
IN2012DN02737A (es)
WO2010032059A3 (en) Antibodies directed to cd105 and uses thereof
WO2009040445A3 (en) Arabinoxylo-oligosaccharides useful against gastrointestinal infections
EA201101189A1 (ru) Ингибитор sglt-2, предназначенный для лечения сахарного диабета типа 1, сахарного диабета типа 2, нарушенной толерантности к глюкозе или гипергликемии
NZ612455A (en) Human milk oligosaccharides to promote growth of beneficial bacteria
MX2009011500A (es) Anticuerpos anti-mdl-1.
AU2008298744A8 (en) MiRNA expression in human peripheral blood microvesicles and uses thereof
MX2012005037A (es) Inmunoglobulinas de dominio variable doble y usos de las mismas.
MX2012004415A (es) Inmunoglobulinas de dominio variable doble y usos de las mismas.
WO2009061447A3 (en) Use of umbilical cord blood in the treatment of premature birth complications
MX2012001262A (es) Inmunoglobulinas de dominio variable doble y usos de las misma.
WO2011127304A3 (en) Methods of treating an overweight subject
NZ602249A (en) Food comprising glucomannan, xanthan gum and alginate for the treatment of metabolic disorders
WO2007127273A3 (en) Methods and compositions for altering cell function
IN2012DN01638A (es)
EA201291441A1 (ru) Пробиотические штаммы для применения при улучшении состояния кишечной нервной системы
IN2012DN00624A (es)
TN2009000241A1 (en) Nutritional supplement composition for treatment of ocular diseases
CA2821268C (en) Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
WO2011035205A3 (en) Antibodies against candida, collections thereof and methods of use

Legal Events

Date Code Title Description
FG Grant or registration